Trial Outcomes & Findings for Tocilizumab for the Prevention of Graft Failure and GVHD in Haplo-Cord Transplantation (NCT NCT04395222)

NCT ID: NCT04395222

Last Updated: 2026-01-06

Results Overview

This is defined as: 1. Achieve an absolute neutrophil count (ANC) of 500 cells/microL for three consecutive days with the first on or prior to Day +21 post-transplant, AND 2. Absence of a second nadir - a drop in the ANC to \<300 cells/microL for five consecutive days - after initial neutrophil recovery.

• Recruitment status: ACTIVE_NOT_RECRUITING
• Study phase: PHASE2
• Target enrollment: 21 participants
• Primary outcome timeframe: 21 days post-transplant
• Results posted on: 2026-01-06

Participant Flow

Participant milestones

Measure	ATG Group I Anti-thymocyte Globulin (ATG) 1.5 mg/kg administered on Day -5, Day -3 and Day -1 of the transplant conditioning regimen. * Fludarabine 30mg/m2 administered on Day -7 through Day -3 of transplant conditioning regimen (if under 60 years old), or on Day -5 through Day -3 of transplant conditioning regimen (if over 60 years old) * Melphalan 140 mg/m2 administered on Day -2 of transplant conditioning regimen. * Total Body Irradiation 2 Gray administered on Day -4, Day -3 of transplant conditioning regimen. * Tocilizumab 8 mg/kg administered on Day -1 of transplant conditioning regimen. Tocilizumab: Tocilizumab 8 mg/kg intravenously administered as a single dose on Day -1 of transplant conditioning regimen Fludarabine: Fludarabine 30 mg/m2 intravenously administered on Day -7, Day -6, Day -5, Day -4, Day -3 of transplant conditioning regimen if under the age of 60. If over the age of 60, Fludarabine 30 mg/m2 intravenously administered on Day -5, Day -4 and Day -3 of transplant conditioning regimen. Melphalan: Melphalan 140 mg/m2 intravenously administered on Day -2 of transplant conditioning regimen. Anti-thymocyte globulin (rabbit): Anti-thymocyte globulin (ATG) 1.5 mg/kg Total Body Irradiation: Total Body Irradiation (TBI) 2 Gray, administered on Day -4 and Day -3 of transplant conditioning regimen	ATG Group II Anti-thymocyte Globulin (ATG) 1.5 mg/kg administered on Day -5, and Day -3 of the transplant conditioning regimen. * Fludarabine 30mg/m2 administered on Day -7 through Day -3 of transplant conditioning regimen (if under 60 years old), or on Day -5 through Day -3 of transplant conditioning regimen (if over 60 years old) * Melphalan 140 mg/m2 administered on Day -2 of transplant conditioning regimen. * Total Body Irradiation 2 Gray administered on Day -4, Day -3 of transplant conditioning regimen. * Tocilizumab 8 mg/kg administered on Day -1 of transplant conditioning regimen. Tocilizumab: Tocilizumab 8 mg/kg intravenously administered as a single dose on Day -1 of transplant conditioning regimen Fludarabine: Fludarabine 30 mg/m2 intravenously administered on Day -7, Day -6, Day -5, Day -4, Day -3 of transplant conditioning regimen if under the age of 60. If over the age of 60, Fludarabine 30 mg/m2 intravenously administered on Day -5, Day -4 and Day -3 of transplant conditioning regimen. Melphalan: Melphalan 140 mg/m2 intravenously administered on Day -2 of transplant conditioning regimen. Anti-thymocyte globulin (rabbit): Anti-thymocyte globulin (ATG) 1.5 mg/kg Total Body Irradiation: Total Body Irradiation (TBI) 2 Gray, administered on Day -4 and Day -3 of transplant conditioning regimen	ATG Group III Anti-thymocyte Globulin (ATG) 1.5 mg/kg administered on Day -5 of the transplant conditioning regimen. * Fludarabine 30mg/m2 administered on Day -7 through Day -3 of transplant conditioning regimen (if under 60 years old), or on Day -5 through Day -3 of transplant conditioning regimen (if over 60 years old) * Melphalan 140 mg/m2 administered on Day -2 of transplant conditioning regimen. * Total Body Irradiation 2 Gray administered on Day -4, Day -3 of transplant conditioning regimen. * Tocilizumab 8 mg/kg administered on Day -1 of transplant conditioning regimen. Tocilizumab: Tocilizumab 8 mg/kg intravenously administered as a single dose on Day -1 of transplant conditioning regimen Fludarabine: Fludarabine 30 mg/m2 intravenously administered on Day -7, Day -6, Day -5, Day -4, Day -3 of transplant conditioning regimen if under the age of 60. If over the age of 60, Fludarabine 30 mg/m2 intravenously administered on Day -5, Day -4 and Day -3 of transplant conditioning regimen. Melphalan: Melphalan 140 mg/m2 intravenously administered on Day -2 of transplant conditioning regimen. Anti-thymocyte globulin (rabbit): Anti-thymocyte globulin (ATG) 1.5 mg/kg Total Body Irradiation: Total Body Irradiation (TBI) 2 Gray, administered on Day -4 and Day -3 of transplant conditioning regimen	ATG Group IV * Fludarabine 30mg/m2 administered on Day -7 through Day -3 of transplant conditioning regimen (if under 60 years old), or on Day -5 through Day -3 of transplant conditioning regimen (if over 60 years old) * Melphalan 140 mg/m2 administered on Day -2 of transplant conditioning regimen. * Total Body Irradiation 2 Gray administered on Day -4, Day -3 of transplant conditioning regimen. * Tocilizumab 8 mg/kg administered on Day -1 of transplant conditioning regimen. Tocilizumab: Tocilizumab 8 mg/kg intravenously administered as a single dose on Day -1 of transplant conditioning regimen Fludarabine: Fludarabine 30 mg/m2 intravenously administered on Day -7, Day -6, Day -5, Day -4, Day -3 of transplant conditioning regimen if under the age of 60. If over the age of 60, Fludarabine 30 mg/m2 intravenously administered on Day -5, Day -4 and Day -3 of transplant conditioning regimen. Melphalan: Melphalan 140 mg/m2 intravenously administered on Day -2 of transplant conditioning regimen. Total Body Irradiation: Total Body Irradiation (TBI) 2 Gray, administered on Day -4 and Day -3 of transplant conditioning regimen
Overall Study STARTED	10	10	1	0
Overall Study COMPLETED	10	10	1	0
Overall Study NOT COMPLETED	0	0	0	0

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Tocilizumab for the Prevention of Graft Failure and GVHD in Haplo-Cord Transplantation

Baseline characteristics by cohort

Measure	ATG Group I n=10 Participants Anti-thymocyte Globulin (ATG) 1.5 mg/kg administered on Day -5, Day -3 and Day -1 of the transplant conditioning regimen. * Fludarabine 30mg/m2 administered on Day -7 through Day -3 of transplant conditioning regimen (if under 60 years old), or on Day -5 through Day -3 of transplant conditioning regimen (if over 60 years old) * Melphalan 140 mg/m2 administered on Day -2 of transplant conditioning regimen. * Total Body Irradiation 2 Gray administered on Day -4, Day -3 of transplant conditioning regimen. * Tocilizumab 8 mg/kg administered on Day -1 of transplant conditioning regimen. Tocilizumab: Tocilizumab 8 mg/kg intravenously administered as a single dose on Day -1 of transplant conditioning regimen Fludarabine: Fludarabine 30 mg/m2 intravenously administered on Day -7, Day -6, Day -5, Day -4, Day -3 of transplant conditioning regimen if under the age of 60. If over the age of 60, Fludarabine 30 mg/m2 intravenously administered on Day -5, Day -4 and Day -3 of transplant conditioning regimen. Melphalan: Melphalan 140 mg/m2 intravenously administered on Day -2 of transplant conditioning regimen. Anti-thymocyte globulin (rabbit): Anti-thymocyte globulin (ATG) 1.5 mg/kg Total Body Irradiation: Total Body Irradiation (TBI) 2 Gray, administered on Day -4 and Day -3 of transplant conditioning regimen	ATG Group II n=10 Participants Anti-thymocyte Globulin (ATG) 1.5 mg/kg administered on Day -5, and Day -3 of the transplant conditioning regimen. * Fludarabine 30mg/m2 administered on Day -7 through Day -3 of transplant conditioning regimen (if under 60 years old), or on Day -5 through Day -3 of transplant conditioning regimen (if over 60 years old) * Melphalan 140 mg/m2 administered on Day -2 of transplant conditioning regimen. * Total Body Irradiation 2 Gray administered on Day -4, Day -3 of transplant conditioning regimen. * Tocilizumab 8 mg/kg administered on Day -1 of transplant conditioning regimen. Tocilizumab: Tocilizumab 8 mg/kg intravenously administered as a single dose on Day -1 of transplant conditioning regimen Fludarabine: Fludarabine 30 mg/m2 intravenously administered on Day -7, Day -6, Day -5, Day -4, Day -3 of transplant conditioning regimen if under the age of 60. If over the age of 60, Fludarabine 30 mg/m2 intravenously administered on Day -5, Day -4 and Day -3 of transplant conditioning regimen. Melphalan: Melphalan 140 mg/m2 intravenously administered on Day -2 of transplant conditioning regimen. Anti-thymocyte globulin (rabbit): Anti-thymocyte globulin (ATG) 1.5 mg/kg Total Body Irradiation: Total Body Irradiation (TBI) 2 Gray, administered on Day -4 and Day -3 of transplant conditioning regimen	ATG Group III n=1 Participants Anti-thymocyte Globulin (ATG) 1.5 mg/kg administered on Day -5 of the transplant conditioning regimen. * Fludarabine 30mg/m2 administered on Day -7 through Day -3 of transplant conditioning regimen (if under 60 years old), or on Day -5 through Day -3 of transplant conditioning regimen (if over 60 years old) * Melphalan 140 mg/m2 administered on Day -2 of transplant conditioning regimen. * Total Body Irradiation 2 Gray administered on Day -4, Day -3 of transplant conditioning regimen. * Tocilizumab 8 mg/kg administered on Day -1 of transplant conditioning regimen. Tocilizumab: Tocilizumab 8 mg/kg intravenously administered as a single dose on Day -1 of transplant conditioning regimen Fludarabine: Fludarabine 30 mg/m2 intravenously administered on Day -7, Day -6, Day -5, Day -4, Day -3 of transplant conditioning regimen if under the age of 60. If over the age of 60, Fludarabine 30 mg/m2 intravenously administered on Day -5, Day -4 and Day -3 of transplant conditioning regimen. Melphalan: Melphalan 140 mg/m2 intravenously administered on Day -2 of transplant conditioning regimen. Anti-thymocyte globulin (rabbit): Anti-thymocyte globulin (ATG) 1.5 mg/kg Total Body Irradiation: Total Body Irradiation (TBI) 2 Gray, administered on Day -4 and Day -3 of transplant conditioning regimen	ATG Group IV * Fludarabine 30mg/m2 administered on Day -7 through Day -3 of transplant conditioning regimen (if under 60 years old), or on Day -5 through Day -3 of transplant conditioning regimen (if over 60 years old) * Melphalan 140 mg/m2 administered on Day -2 of transplant conditioning regimen. * Total Body Irradiation 2 Gray administered on Day -4, Day -3 of transplant conditioning regimen. * Tocilizumab 8 mg/kg administered on Day -1 of transplant conditioning regimen. Tocilizumab: Tocilizumab 8 mg/kg intravenously administered as a single dose on Day -1 of transplant conditioning regimen Fludarabine: Fludarabine 30 mg/m2 intravenously administered on Day -7, Day -6, Day -5, Day -4, Day -3 of transplant conditioning regimen if under the age of 60. If over the age of 60, Fludarabine 30 mg/m2 intravenously administered on Day -5, Day -4 and Day -3 of transplant conditioning regimen. Melphalan: Melphalan 140 mg/m2 intravenously administered on Day -2 of transplant conditioning regimen. Total Body Irradiation: Total Body Irradiation (TBI) 2 Gray, administered on Day -4 and Day -3 of transplant conditioning regimen	Total n=21 Participants Total of all reporting groups
Age, Customized 18-29 years	1 Participants n=37 Participants	2 Participants n=56 Participants	0 Participants n=82 Participants	0 Participants n=31 Participants	3 Participants n=5 Participants
Age, Customized 30-39 years	1 Participants n=37 Participants	2 Participants n=56 Participants	0 Participants n=82 Participants	0 Participants n=31 Participants	3 Participants n=5 Participants
Age, Customized 40-49 years	1 Participants n=37 Participants	2 Participants n=56 Participants	0 Participants n=82 Participants	0 Participants n=31 Participants	3 Participants n=5 Participants
Age, Customized 50-59 years	0 Participants n=37 Participants	1 Participants n=56 Participants	0 Participants n=82 Participants	0 Participants n=31 Participants	1 Participants n=5 Participants
Age, Customized 60-69 years	7 Participants n=37 Participants	3 Participants n=56 Participants	1 Participants n=82 Participants	0 Participants n=31 Participants	11 Participants n=5 Participants
Sex: Female, Male Female	5 Participants n=37 Participants	5 Participants n=56 Participants	1 Participants n=82 Participants	0 Participants n=31 Participants	11 Participants n=5 Participants
Sex: Female, Male Male	5 Participants n=37 Participants	5 Participants n=56 Participants	0 Participants n=82 Participants	0 Participants n=31 Participants	10 Participants n=5 Participants
Ethnicity (NIH/OMB) Hispanic or Latino	1 Participants n=37 Participants	3 Participants n=56 Participants	0 Participants n=82 Participants	0 Participants n=31 Participants	4 Participants n=5 Participants
Ethnicity (NIH/OMB) Not Hispanic or Latino	8 Participants n=37 Participants	7 Participants n=56 Participants	1 Participants n=82 Participants	0 Participants n=31 Participants	16 Participants n=5 Participants
Ethnicity (NIH/OMB) Unknown or Not Reported	1 Participants n=37 Participants	0 Participants n=56 Participants	0 Participants n=82 Participants	0 Participants n=31 Participants	1 Participants n=5 Participants
Race (NIH/OMB) American Indian or Alaska Native	0 Participants n=37 Participants	0 Participants n=56 Participants	0 Participants n=82 Participants	0 Participants n=31 Participants	0 Participants n=5 Participants
Race (NIH/OMB) Asian	1 Participants n=37 Participants	1 Participants n=56 Participants	0 Participants n=82 Participants	0 Participants n=31 Participants	2 Participants n=5 Participants
Race (NIH/OMB) Native Hawaiian or Other Pacific Islander	0 Participants n=37 Participants	0 Participants n=56 Participants	0 Participants n=82 Participants	0 Participants n=31 Participants	0 Participants n=5 Participants
Race (NIH/OMB) Black or African American	1 Participants n=37 Participants	2 Participants n=56 Participants	0 Participants n=82 Participants	0 Participants n=31 Participants	3 Participants n=5 Participants
Race (NIH/OMB) White	8 Participants n=37 Participants	6 Participants n=56 Participants	1 Participants n=82 Participants	0 Participants n=31 Participants	15 Participants n=5 Participants
Race (NIH/OMB) More than one race	0 Participants n=37 Participants	0 Participants n=56 Participants	0 Participants n=82 Participants	0 Participants n=31 Participants	0 Participants n=5 Participants
Race (NIH/OMB) Unknown or Not Reported	0 Participants n=37 Participants	1 Participants n=56 Participants	0 Participants n=82 Participants	0 Participants n=31 Participants	1 Participants n=5 Participants
Region of Enrollment United States	10 participants n=37 Participants	10 participants n=56 Participants	1 participants n=82 Participants	—	21 participants n=5 Participants
Primary Malignancy Acute Myeloid Leukemia	5 Participants n=37 Participants	5 Participants n=56 Participants	0 Participants n=82 Participants	0 Participants n=31 Participants	10 Participants n=5 Participants
Primary Malignancy Myelodysplastic Syndrome	1 Participants n=37 Participants	3 Participants n=56 Participants	1 Participants n=82 Participants	0 Participants n=31 Participants	5 Participants n=5 Participants
Primary Malignancy Myeloproliferative Neoplasm	1 Participants n=37 Participants	1 Participants n=56 Participants	0 Participants n=82 Participants	0 Participants n=31 Participants	2 Participants n=5 Participants
Primary Malignancy Non-Hodgkin Lymphoma	2 Participants n=37 Participants	1 Participants n=56 Participants	0 Participants n=82 Participants	0 Participants n=31 Participants	3 Participants n=5 Participants
Primary Malignancy Other Acute Leukemia	1 Participants n=37 Participants	0 Participants n=56 Participants	0 Participants n=82 Participants	0 Participants n=31 Participants	1 Participants n=5 Participants

PRIMARY outcome

Timeframe: 21 days post-transplant

Population: No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.

This is defined as:

1. Achieve an absolute neutrophil count (ANC) of 500 cells/microL for three consecutive days with the first on or prior to Day +21 post-transplant, AND

2. Absence of a second nadir - a drop in the ANC to <300 cells/microL for five consecutive days - after initial neutrophil recovery.

Outcome measures

Measure	ATG Group I n=10 Participants Anti-thymocyte Globulin (ATG) 1.5 mg/kg administered on Day -5, Day -3 and Day -1 of the transplant conditioning regimen. * Fludarabine 30mg/m2 administered on Day -7 through Day -3 of transplant conditioning regimen (if under 60 years old), or on Day -5 through Day -3 of transplant conditioning regimen (if over 60 years old) * Melphalan 140 mg/m2 administered on Day -2 of transplant conditioning regimen. * Total Body Irradiation 2 Gray administered on Day -4, Day -3 of transplant conditioning regimen. * Tocilizumab 8 mg/kg administered on Day -1 of transplant conditioning regimen. Tocilizumab: Tocilizumab 8 mg/kg intravenously administered as a single dose on Day -1 of transplant conditioning regimen Fludarabine: Fludarabine 30 mg/m2 intravenously administered on Day -7, Day -6, Day -5, Day -4, Day -3 of transplant conditioning regimen if under the age of 60. If over the age of 60, Fludarabine 30 mg/m2 intravenously administered on Day -5, Day -4 and Day -3 of transplant conditioning regimen. Melphalan: Melphalan 140 mg/m2 intravenously administered on Day -2 of transplant conditioning regimen. Anti-thymocyte globulin (rabbit): Anti-thymocyte globulin (ATG) 1.5 mg/kg Total Body Irradiation: Total Body Irradiation (TBI) 2 Gray, administered on Day -4 and Day -3 of transplant conditioning regimen	ATG Group II n=10 Participants Anti-thymocyte Globulin (ATG) 1.5 mg/kg administered on Day -5, and Day -3 of the transplant conditioning regimen. * Fludarabine 30mg/m2 administered on Day -7 through Day -3 of transplant conditioning regimen (if under 60 years old), or on Day -5 through Day -3 of transplant conditioning regimen (if over 60 years old) * Melphalan 140 mg/m2 administered on Day -2 of transplant conditioning regimen. * Total Body Irradiation 2 Gray administered on Day -4, Day -3 of transplant conditioning regimen. * Tocilizumab 8 mg/kg administered on Day -1 of transplant conditioning regimen. Tocilizumab: Tocilizumab 8 mg/kg intravenously administered as a single dose on Day -1 of transplant conditioning regimen Fludarabine: Fludarabine 30 mg/m2 intravenously administered on Day -7, Day -6, Day -5, Day -4, Day -3 of transplant conditioning regimen if under the age of 60. If over the age of 60, Fludarabine 30 mg/m2 intravenously administered on Day -5, Day -4 and Day -3 of transplant conditioning regimen. Melphalan: Melphalan 140 mg/m2 intravenously administered on Day -2 of transplant conditioning regimen. Anti-thymocyte globulin (rabbit): Anti-thymocyte globulin (ATG) 1.5 mg/kg Total Body Irradiation: Total Body Irradiation (TBI) 2 Gray, administered on Day -4 and Day -3 of transplant conditioning regimen	ATG Group III n=1 Participants Anti-thymocyte Globulin (ATG) 1.5 mg/kg administered on Day -5 of the transplant conditioning regimen. * Fludarabine 30mg/m2 administered on Day -7 through Day -3 of transplant conditioning regimen (if under 60 years old), or on Day -5 through Day -3 of transplant conditioning regimen (if over 60 years old) * Melphalan 140 mg/m2 administered on Day -2 of transplant conditioning regimen. * Total Body Irradiation 2 Gray administered on Day -4, Day -3 of transplant conditioning regimen. * Tocilizumab 8 mg/kg administered on Day -1 of transplant conditioning regimen. Tocilizumab: Tocilizumab 8 mg/kg intravenously administered as a single dose on Day -1 of transplant conditioning regimen Fludarabine: Fludarabine 30 mg/m2 intravenously administered on Day -7, Day -6, Day -5, Day -4, Day -3 of transplant conditioning regimen if under the age of 60. If over the age of 60, Fludarabine 30 mg/m2 intravenously administered on Day -5, Day -4 and Day -3 of transplant conditioning regimen. Melphalan: Melphalan 140 mg/m2 intravenously administered on Day -2 of transplant conditioning regimen. Anti-thymocyte globulin (rabbit): Anti-thymocyte globulin (ATG) 1.5 mg/kg Total Body Irradiation: Total Body Irradiation (TBI) 2 Gray, administered on Day -4 and Day -3 of transplant conditioning regimen	ATG Group IV * Fludarabine 30mg/m2 administered on Day -7 through Day -3 of transplant conditioning regimen (if under 60 years old), or on Day -5 through Day -3 of transplant conditioning regimen (if over 60 years old) * Melphalan 140 mg/m2 administered on Day -2 of transplant conditioning regimen. * Total Body Irradiation 2 Gray administered on Day -4, Day -3 of transplant conditioning regimen. * Tocilizumab 8 mg/kg administered on Day -1 of transplant conditioning regimen. Tocilizumab: Tocilizumab 8 mg/kg intravenously administered as a single dose on Day -1 of transplant conditioning regimen Fludarabine: Fludarabine 30 mg/m2 intravenously administered on Day -7, Day -6, Day -5, Day -4, Day -3 of transplant conditioning regimen if under the age of 60. If over the age of 60, Fludarabine 30 mg/m2 intravenously administered on Day -5, Day -4 and Day -3 of transplant conditioning regimen. Melphalan: Melphalan 140 mg/m2 intravenously administered on Day -2 of transplant conditioning regimen. Total Body Irradiation: Total Body Irradiation (TBI) 2 Gray, administered on Day -4 and Day -3 of transplant conditioning regimen
Percentage of Subjects With Successful Haplo-derived Neutrophil Engraftment	80 percentage of participants	50 percentage of participants	0 percentage of participants	—

SECONDARY outcome

Timeframe: 5 years post-transplant

Time elapsed between Day 0 and progression of the underlying malignancy for which the transplant was performed, assessed up to 5 years post-transplant.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: 5 years post-transplant

Time elapsed between Day 0 and death from any cause, assessed up to 5 years post-transplant.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: 5 years post-transplant

Proportion of deaths which cannot be explained by persistence, relapse or progression of the underlying malignancy once the preparative regimen starts, assessed up to 5 years post-transplant.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: 6 months post-transplant

Population: No subjects were enrolled to ATG Group IV, study enrollment was stopped before accrual reached that cohort.

Proportion of patients who successfully achieve platelet engraftment, defined as a platelet count of >20k/microL for three consecutive days without transfusion support for seven consecutive days.

Outcome measures

Measure	ATG Group I n=10 Participants Anti-thymocyte Globulin (ATG) 1.5 mg/kg administered on Day -5, Day -3 and Day -1 of the transplant conditioning regimen. * Fludarabine 30mg/m2 administered on Day -7 through Day -3 of transplant conditioning regimen (if under 60 years old), or on Day -5 through Day -3 of transplant conditioning regimen (if over 60 years old) * Melphalan 140 mg/m2 administered on Day -2 of transplant conditioning regimen. * Total Body Irradiation 2 Gray administered on Day -4, Day -3 of transplant conditioning regimen. * Tocilizumab 8 mg/kg administered on Day -1 of transplant conditioning regimen. Tocilizumab: Tocilizumab 8 mg/kg intravenously administered as a single dose on Day -1 of transplant conditioning regimen Fludarabine: Fludarabine 30 mg/m2 intravenously administered on Day -7, Day -6, Day -5, Day -4, Day -3 of transplant conditioning regimen if under the age of 60. If over the age of 60, Fludarabine 30 mg/m2 intravenously administered on Day -5, Day -4 and Day -3 of transplant conditioning regimen. Melphalan: Melphalan 140 mg/m2 intravenously administered on Day -2 of transplant conditioning regimen. Anti-thymocyte globulin (rabbit): Anti-thymocyte globulin (ATG) 1.5 mg/kg Total Body Irradiation: Total Body Irradiation (TBI) 2 Gray, administered on Day -4 and Day -3 of transplant conditioning regimen	ATG Group II n=10 Participants Anti-thymocyte Globulin (ATG) 1.5 mg/kg administered on Day -5, and Day -3 of the transplant conditioning regimen. * Fludarabine 30mg/m2 administered on Day -7 through Day -3 of transplant conditioning regimen (if under 60 years old), or on Day -5 through Day -3 of transplant conditioning regimen (if over 60 years old) * Melphalan 140 mg/m2 administered on Day -2 of transplant conditioning regimen. * Total Body Irradiation 2 Gray administered on Day -4, Day -3 of transplant conditioning regimen. * Tocilizumab 8 mg/kg administered on Day -1 of transplant conditioning regimen. Tocilizumab: Tocilizumab 8 mg/kg intravenously administered as a single dose on Day -1 of transplant conditioning regimen Fludarabine: Fludarabine 30 mg/m2 intravenously administered on Day -7, Day -6, Day -5, Day -4, Day -3 of transplant conditioning regimen if under the age of 60. If over the age of 60, Fludarabine 30 mg/m2 intravenously administered on Day -5, Day -4 and Day -3 of transplant conditioning regimen. Melphalan: Melphalan 140 mg/m2 intravenously administered on Day -2 of transplant conditioning regimen. Anti-thymocyte globulin (rabbit): Anti-thymocyte globulin (ATG) 1.5 mg/kg Total Body Irradiation: Total Body Irradiation (TBI) 2 Gray, administered on Day -4 and Day -3 of transplant conditioning regimen	ATG Group III n=1 Participants Anti-thymocyte Globulin (ATG) 1.5 mg/kg administered on Day -5 of the transplant conditioning regimen. * Fludarabine 30mg/m2 administered on Day -7 through Day -3 of transplant conditioning regimen (if under 60 years old), or on Day -5 through Day -3 of transplant conditioning regimen (if over 60 years old) * Melphalan 140 mg/m2 administered on Day -2 of transplant conditioning regimen. * Total Body Irradiation 2 Gray administered on Day -4, Day -3 of transplant conditioning regimen. * Tocilizumab 8 mg/kg administered on Day -1 of transplant conditioning regimen. Tocilizumab: Tocilizumab 8 mg/kg intravenously administered as a single dose on Day -1 of transplant conditioning regimen Fludarabine: Fludarabine 30 mg/m2 intravenously administered on Day -7, Day -6, Day -5, Day -4, Day -3 of transplant conditioning regimen if under the age of 60. If over the age of 60, Fludarabine 30 mg/m2 intravenously administered on Day -5, Day -4 and Day -3 of transplant conditioning regimen. Melphalan: Melphalan 140 mg/m2 intravenously administered on Day -2 of transplant conditioning regimen. Anti-thymocyte globulin (rabbit): Anti-thymocyte globulin (ATG) 1.5 mg/kg Total Body Irradiation: Total Body Irradiation (TBI) 2 Gray, administered on Day -4 and Day -3 of transplant conditioning regimen	ATG Group IV * Fludarabine 30mg/m2 administered on Day -7 through Day -3 of transplant conditioning regimen (if under 60 years old), or on Day -5 through Day -3 of transplant conditioning regimen (if over 60 years old) * Melphalan 140 mg/m2 administered on Day -2 of transplant conditioning regimen. * Total Body Irradiation 2 Gray administered on Day -4, Day -3 of transplant conditioning regimen. * Tocilizumab 8 mg/kg administered on Day -1 of transplant conditioning regimen. Tocilizumab: Tocilizumab 8 mg/kg intravenously administered as a single dose on Day -1 of transplant conditioning regimen Fludarabine: Fludarabine 30 mg/m2 intravenously administered on Day -7, Day -6, Day -5, Day -4, Day -3 of transplant conditioning regimen if under the age of 60. If over the age of 60, Fludarabine 30 mg/m2 intravenously administered on Day -5, Day -4 and Day -3 of transplant conditioning regimen. Melphalan: Melphalan 140 mg/m2 intravenously administered on Day -2 of transplant conditioning regimen. Total Body Irradiation: Total Body Irradiation (TBI) 2 Gray, administered on Day -4 and Day -3 of transplant conditioning regimen
Proportion of Platelet Engraftment Success	10 Participants	10 Participants	0 Participants	0 Participants

SECONDARY outcome

Timeframe: 21 days post-transplant

Population: No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.

Proportion of patients with a failed haplo-graft, defined as the absence of neutrophil engraftment by Day +21 or a drop in the absolute neutrophil count to <0.3 cells/microL for five consecutive days occurring after initial neutrophil engraftment within the first 3 weeks post-transplantation (second nadir)

Outcome measures

Measure	ATG Group I n=10 Participants Anti-thymocyte Globulin (ATG) 1.5 mg/kg administered on Day -5, Day -3 and Day -1 of the transplant conditioning regimen. * Fludarabine 30mg/m2 administered on Day -7 through Day -3 of transplant conditioning regimen (if under 60 years old), or on Day -5 through Day -3 of transplant conditioning regimen (if over 60 years old) * Melphalan 140 mg/m2 administered on Day -2 of transplant conditioning regimen. * Total Body Irradiation 2 Gray administered on Day -4, Day -3 of transplant conditioning regimen. * Tocilizumab 8 mg/kg administered on Day -1 of transplant conditioning regimen. Tocilizumab: Tocilizumab 8 mg/kg intravenously administered as a single dose on Day -1 of transplant conditioning regimen Fludarabine: Fludarabine 30 mg/m2 intravenously administered on Day -7, Day -6, Day -5, Day -4, Day -3 of transplant conditioning regimen if under the age of 60. If over the age of 60, Fludarabine 30 mg/m2 intravenously administered on Day -5, Day -4 and Day -3 of transplant conditioning regimen. Melphalan: Melphalan 140 mg/m2 intravenously administered on Day -2 of transplant conditioning regimen. Anti-thymocyte globulin (rabbit): Anti-thymocyte globulin (ATG) 1.5 mg/kg Total Body Irradiation: Total Body Irradiation (TBI) 2 Gray, administered on Day -4 and Day -3 of transplant conditioning regimen	ATG Group II n=10 Participants Anti-thymocyte Globulin (ATG) 1.5 mg/kg administered on Day -5, and Day -3 of the transplant conditioning regimen. * Fludarabine 30mg/m2 administered on Day -7 through Day -3 of transplant conditioning regimen (if under 60 years old), or on Day -5 through Day -3 of transplant conditioning regimen (if over 60 years old) * Melphalan 140 mg/m2 administered on Day -2 of transplant conditioning regimen. * Total Body Irradiation 2 Gray administered on Day -4, Day -3 of transplant conditioning regimen. * Tocilizumab 8 mg/kg administered on Day -1 of transplant conditioning regimen. Tocilizumab: Tocilizumab 8 mg/kg intravenously administered as a single dose on Day -1 of transplant conditioning regimen Fludarabine: Fludarabine 30 mg/m2 intravenously administered on Day -7, Day -6, Day -5, Day -4, Day -3 of transplant conditioning regimen if under the age of 60. If over the age of 60, Fludarabine 30 mg/m2 intravenously administered on Day -5, Day -4 and Day -3 of transplant conditioning regimen. Melphalan: Melphalan 140 mg/m2 intravenously administered on Day -2 of transplant conditioning regimen. Anti-thymocyte globulin (rabbit): Anti-thymocyte globulin (ATG) 1.5 mg/kg Total Body Irradiation: Total Body Irradiation (TBI) 2 Gray, administered on Day -4 and Day -3 of transplant conditioning regimen	ATG Group III n=1 Participants Anti-thymocyte Globulin (ATG) 1.5 mg/kg administered on Day -5 of the transplant conditioning regimen. * Fludarabine 30mg/m2 administered on Day -7 through Day -3 of transplant conditioning regimen (if under 60 years old), or on Day -5 through Day -3 of transplant conditioning regimen (if over 60 years old) * Melphalan 140 mg/m2 administered on Day -2 of transplant conditioning regimen. * Total Body Irradiation 2 Gray administered on Day -4, Day -3 of transplant conditioning regimen. * Tocilizumab 8 mg/kg administered on Day -1 of transplant conditioning regimen. Tocilizumab: Tocilizumab 8 mg/kg intravenously administered as a single dose on Day -1 of transplant conditioning regimen Fludarabine: Fludarabine 30 mg/m2 intravenously administered on Day -7, Day -6, Day -5, Day -4, Day -3 of transplant conditioning regimen if under the age of 60. If over the age of 60, Fludarabine 30 mg/m2 intravenously administered on Day -5, Day -4 and Day -3 of transplant conditioning regimen. Melphalan: Melphalan 140 mg/m2 intravenously administered on Day -2 of transplant conditioning regimen. Anti-thymocyte globulin (rabbit): Anti-thymocyte globulin (ATG) 1.5 mg/kg Total Body Irradiation: Total Body Irradiation (TBI) 2 Gray, administered on Day -4 and Day -3 of transplant conditioning regimen	ATG Group IV * Fludarabine 30mg/m2 administered on Day -7 through Day -3 of transplant conditioning regimen (if under 60 years old), or on Day -5 through Day -3 of transplant conditioning regimen (if over 60 years old) * Melphalan 140 mg/m2 administered on Day -2 of transplant conditioning regimen. * Total Body Irradiation 2 Gray administered on Day -4, Day -3 of transplant conditioning regimen. * Tocilizumab 8 mg/kg administered on Day -1 of transplant conditioning regimen. Tocilizumab: Tocilizumab 8 mg/kg intravenously administered as a single dose on Day -1 of transplant conditioning regimen Fludarabine: Fludarabine 30 mg/m2 intravenously administered on Day -7, Day -6, Day -5, Day -4, Day -3 of transplant conditioning regimen if under the age of 60. If over the age of 60, Fludarabine 30 mg/m2 intravenously administered on Day -5, Day -4 and Day -3 of transplant conditioning regimen. Melphalan: Melphalan 140 mg/m2 intravenously administered on Day -2 of transplant conditioning regimen. Total Body Irradiation: Total Body Irradiation (TBI) 2 Gray, administered on Day -4 and Day -3 of transplant conditioning regimen
Proportion of Failure of the Haplo-Graft	2 Participants	5 Participants	1 Participants	—

SECONDARY outcome

Timeframe: 1 year post-transplant

Population: No subjects were enrolled to ATG Group IV, study enrollment was stopped before accrual reached that cohort.

Proportion of patients who develop acute graft-versus-host disease

Outcome measures

Measure	ATG Group I n=10 Participants Anti-thymocyte Globulin (ATG) 1.5 mg/kg administered on Day -5, Day -3 and Day -1 of the transplant conditioning regimen. * Fludarabine 30mg/m2 administered on Day -7 through Day -3 of transplant conditioning regimen (if under 60 years old), or on Day -5 through Day -3 of transplant conditioning regimen (if over 60 years old) * Melphalan 140 mg/m2 administered on Day -2 of transplant conditioning regimen. * Total Body Irradiation 2 Gray administered on Day -4, Day -3 of transplant conditioning regimen. * Tocilizumab 8 mg/kg administered on Day -1 of transplant conditioning regimen. Tocilizumab: Tocilizumab 8 mg/kg intravenously administered as a single dose on Day -1 of transplant conditioning regimen Fludarabine: Fludarabine 30 mg/m2 intravenously administered on Day -7, Day -6, Day -5, Day -4, Day -3 of transplant conditioning regimen if under the age of 60. If over the age of 60, Fludarabine 30 mg/m2 intravenously administered on Day -5, Day -4 and Day -3 of transplant conditioning regimen. Melphalan: Melphalan 140 mg/m2 intravenously administered on Day -2 of transplant conditioning regimen. Anti-thymocyte globulin (rabbit): Anti-thymocyte globulin (ATG) 1.5 mg/kg Total Body Irradiation: Total Body Irradiation (TBI) 2 Gray, administered on Day -4 and Day -3 of transplant conditioning regimen	ATG Group II n=10 Participants Anti-thymocyte Globulin (ATG) 1.5 mg/kg administered on Day -5, and Day -3 of the transplant conditioning regimen. * Fludarabine 30mg/m2 administered on Day -7 through Day -3 of transplant conditioning regimen (if under 60 years old), or on Day -5 through Day -3 of transplant conditioning regimen (if over 60 years old) * Melphalan 140 mg/m2 administered on Day -2 of transplant conditioning regimen. * Total Body Irradiation 2 Gray administered on Day -4, Day -3 of transplant conditioning regimen. * Tocilizumab 8 mg/kg administered on Day -1 of transplant conditioning regimen. Tocilizumab: Tocilizumab 8 mg/kg intravenously administered as a single dose on Day -1 of transplant conditioning regimen Fludarabine: Fludarabine 30 mg/m2 intravenously administered on Day -7, Day -6, Day -5, Day -4, Day -3 of transplant conditioning regimen if under the age of 60. If over the age of 60, Fludarabine 30 mg/m2 intravenously administered on Day -5, Day -4 and Day -3 of transplant conditioning regimen. Melphalan: Melphalan 140 mg/m2 intravenously administered on Day -2 of transplant conditioning regimen. Anti-thymocyte globulin (rabbit): Anti-thymocyte globulin (ATG) 1.5 mg/kg Total Body Irradiation: Total Body Irradiation (TBI) 2 Gray, administered on Day -4 and Day -3 of transplant conditioning regimen	ATG Group III n=1 Participants Anti-thymocyte Globulin (ATG) 1.5 mg/kg administered on Day -5 of the transplant conditioning regimen. * Fludarabine 30mg/m2 administered on Day -7 through Day -3 of transplant conditioning regimen (if under 60 years old), or on Day -5 through Day -3 of transplant conditioning regimen (if over 60 years old) * Melphalan 140 mg/m2 administered on Day -2 of transplant conditioning regimen. * Total Body Irradiation 2 Gray administered on Day -4, Day -3 of transplant conditioning regimen. * Tocilizumab 8 mg/kg administered on Day -1 of transplant conditioning regimen. Tocilizumab: Tocilizumab 8 mg/kg intravenously administered as a single dose on Day -1 of transplant conditioning regimen Fludarabine: Fludarabine 30 mg/m2 intravenously administered on Day -7, Day -6, Day -5, Day -4, Day -3 of transplant conditioning regimen if under the age of 60. If over the age of 60, Fludarabine 30 mg/m2 intravenously administered on Day -5, Day -4 and Day -3 of transplant conditioning regimen. Melphalan: Melphalan 140 mg/m2 intravenously administered on Day -2 of transplant conditioning regimen. Anti-thymocyte globulin (rabbit): Anti-thymocyte globulin (ATG) 1.5 mg/kg Total Body Irradiation: Total Body Irradiation (TBI) 2 Gray, administered on Day -4 and Day -3 of transplant conditioning regimen	ATG Group IV * Fludarabine 30mg/m2 administered on Day -7 through Day -3 of transplant conditioning regimen (if under 60 years old), or on Day -5 through Day -3 of transplant conditioning regimen (if over 60 years old) * Melphalan 140 mg/m2 administered on Day -2 of transplant conditioning regimen. * Total Body Irradiation 2 Gray administered on Day -4, Day -3 of transplant conditioning regimen. * Tocilizumab 8 mg/kg administered on Day -1 of transplant conditioning regimen. Tocilizumab: Tocilizumab 8 mg/kg intravenously administered as a single dose on Day -1 of transplant conditioning regimen Fludarabine: Fludarabine 30 mg/m2 intravenously administered on Day -7, Day -6, Day -5, Day -4, Day -3 of transplant conditioning regimen if under the age of 60. If over the age of 60, Fludarabine 30 mg/m2 intravenously administered on Day -5, Day -4 and Day -3 of transplant conditioning regimen. Melphalan: Melphalan 140 mg/m2 intravenously administered on Day -2 of transplant conditioning regimen. Total Body Irradiation: Total Body Irradiation (TBI) 2 Gray, administered on Day -4 and Day -3 of transplant conditioning regimen
Proportion of Acute Graft-versus-Host Disease	2 Participants	1 Participants	1 Participants	0 Participants

SECONDARY outcome

Timeframe: 5 years post-transplant

Percentage of patients who develop chronic graft-versus-host disease

Outcome measures

Outcome data not reported

Adverse Events

ATG Group I

Serious events: 8 serious events

Other events: 10 other events

Deaths: 5 deaths

ATG Group II

Serious events: 9 serious events

Other events: 10 other events

Deaths: 1 deaths

ATG Group III

Serious events: 1 serious events

Other events: 1 other events

Deaths: 1 deaths

ATG Group IV

Serious events: 0 serious events

Other events: 0 other events

Deaths: 0 deaths

Serious adverse events

Measure	ATG Group I n=10 participants at risk Anti-thymocyte Globulin (ATG) 1.5 mg/kg administered on Day -5, Day -3 and Day -1 of the transplant conditioning regimen. * Fludarabine 30mg/m2 administered on Day -7 through Day -3 of transplant conditioning regimen (if under 60 years old), or on Day -5 through Day -3 of transplant conditioning regimen (if over 60 years old) * Melphalan 140 mg/m2 administered on Day -2 of transplant conditioning regimen. * Total Body Irradiation 2 Gray administered on Day -4, Day -3 of transplant conditioning regimen. * Tocilizumab 8 mg/kg administered on Day -1 of transplant conditioning regimen. Tocilizumab: Tocilizumab 8 mg/kg intravenously administered as a single dose on Day -1 of transplant conditioning regimen Fludarabine: Fludarabine 30 mg/m2 intravenously administered on Day -7, Day -6, Day -5, Day -4, Day -3 of transplant conditioning regimen if under the age of 60. If over the age of 60, Fludarabine 30 mg/m2 intravenously administered on Day -5, Day -4 and Day -3 of transplant conditioning regimen. Melphalan: Melphalan 140 mg/m2 intravenously administered on Day -2 of transplant conditioning regimen. Anti-thymocyte globulin (rabbit): Anti-thymocyte globulin (ATG) 1.5 mg/kg Total Body Irradiation: Total Body Irradiation (TBI) 2 Gray, administered on Day -4 and Day -3 of transplant conditioning regimen	ATG Group II n=10 participants at risk Anti-thymocyte Globulin (ATG) 1.5 mg/kg administered on Day -5, and Day -3 of the transplant conditioning regimen. * Fludarabine 30mg/m2 administered on Day -7 through Day -3 of transplant conditioning regimen (if under 60 years old), or on Day -5 through Day -3 of transplant conditioning regimen (if over 60 years old) * Melphalan 140 mg/m2 administered on Day -2 of transplant conditioning regimen. * Total Body Irradiation 2 Gray administered on Day -4, Day -3 of transplant conditioning regimen. * Tocilizumab 8 mg/kg administered on Day -1 of transplant conditioning regimen. Tocilizumab: Tocilizumab 8 mg/kg intravenously administered as a single dose on Day -1 of transplant conditioning regimen Fludarabine: Fludarabine 30 mg/m2 intravenously administered on Day -7, Day -6, Day -5, Day -4, Day -3 of transplant conditioning regimen if under the age of 60. If over the age of 60, Fludarabine 30 mg/m2 intravenously administered on Day -5, Day -4 and Day -3 of transplant conditioning regimen. Melphalan: Melphalan 140 mg/m2 intravenously administered on Day -2 of transplant conditioning regimen. Anti-thymocyte globulin (rabbit): Anti-thymocyte globulin (ATG) 1.5 mg/kg Total Body Irradiation: Total Body Irradiation (TBI) 2 Gray, administered on Day -4 and Day -3 of transplant conditioning regimen	ATG Group III n=1 participants at risk Anti-thymocyte Globulin (ATG) 1.5 mg/kg administered on Day -5 of the transplant conditioning regimen. * Fludarabine 30mg/m2 administered on Day -7 through Day -3 of transplant conditioning regimen (if under 60 years old), or on Day -5 through Day -3 of transplant conditioning regimen (if over 60 years old) * Melphalan 140 mg/m2 administered on Day -2 of transplant conditioning regimen. * Total Body Irradiation 2 Gray administered on Day -4, Day -3 of transplant conditioning regimen. * Tocilizumab 8 mg/kg administered on Day -1 of transplant conditioning regimen. Tocilizumab: Tocilizumab 8 mg/kg intravenously administered as a single dose on Day -1 of transplant conditioning regimen Fludarabine: Fludarabine 30 mg/m2 intravenously administered on Day -7, Day -6, Day -5, Day -4, Day -3 of transplant conditioning regimen if under the age of 60. If over the age of 60, Fludarabine 30 mg/m2 intravenously administered on Day -5, Day -4 and Day -3 of transplant conditioning regimen. Melphalan: Melphalan 140 mg/m2 intravenously administered on Day -2 of transplant conditioning regimen. Anti-thymocyte globulin (rabbit): Anti-thymocyte globulin (ATG) 1.5 mg/kg Total Body Irradiation: Total Body Irradiation (TBI) 2 Gray, administered on Day -4 and Day -3 of transplant conditioning regimen	ATG Group IV * Fludarabine 30mg/m2 administered on Day -7 through Day -3 of transplant conditioning regimen (if under 60 years old), or on Day -5 through Day -3 of transplant conditioning regimen (if over 60 years old) * Melphalan 140 mg/m2 administered on Day -2 of transplant conditioning regimen. * Total Body Irradiation 2 Gray administered on Day -4, Day -3 of transplant conditioning regimen. * Tocilizumab 8 mg/kg administered on Day -1 of transplant conditioning regimen. Tocilizumab: Tocilizumab 8 mg/kg intravenously administered as a single dose on Day -1 of transplant conditioning regimen Fludarabine: Fludarabine 30 mg/m2 intravenously administered on Day -7, Day -6, Day -5, Day -4, Day -3 of transplant conditioning regimen if under the age of 60. If over the age of 60, Fludarabine 30 mg/m2 intravenously administered on Day -5, Day -4 and Day -3 of transplant conditioning regimen. Melphalan: Melphalan 140 mg/m2 intravenously administered on Day -2 of transplant conditioning regimen. Total Body Irradiation: Total Body Irradiation (TBI) 2 Gray, administered on Day -4 and Day -3 of transplant conditioning regimen
Investigations Acute Graft-versus-Host Disease	10.0% 1/10 • Number of events 1 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.	0.00% 0/10 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.	100.0% 1/1 • Number of events 1 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.	— 0/0 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.
Infections and infestations Bacteremia	20.0% 2/10 • Number of events 2 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.	20.0% 2/10 • Number of events 2 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.	0.00% 0/1 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.	— 0/0 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.
Blood and lymphatic system disorders Hemophagocytic lymphohistiocytosis	0.00% 0/10 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.	10.0% 1/10 • Number of events 1 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.	0.00% 0/1 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.	— 0/0 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.
Hepatobiliary disorders Cholecystitis	10.0% 1/10 • Number of events 1 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.	0.00% 0/10 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.	0.00% 0/1 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.	— 0/0 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.
Infections and infestations Colitis - Cytomegalovirus	0.00% 0/10 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.	10.0% 1/10 • Number of events 1 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.	0.00% 0/1 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.	— 0/0 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.
Gastrointestinal disorders Colitis	0.00% 0/10 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.	10.0% 1/10 • Number of events 1 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.	0.00% 0/1 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.	— 0/0 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.
Respiratory, thoracic and mediastinal disorders Cough	0.00% 0/10 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.	10.0% 1/10 • Number of events 1 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.	0.00% 0/1 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.	— 0/0 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.
Investigations Delayed Engraftment	0.00% 0/10 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.	0.00% 0/10 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.	100.0% 1/1 • Number of events 1 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.	— 0/0 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.
Gastrointestinal disorders Diarrhea	20.0% 2/10 • Number of events 2 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.	10.0% 1/10 • Number of events 1 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.	0.00% 0/1 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.	— 0/0 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.
Respiratory, thoracic and mediastinal disorders Dyspnea	10.0% 1/10 • Number of events 1 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.	0.00% 0/10 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.	0.00% 0/1 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.	— 0/0 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.
Gastrointestinal disorders Enterocolitis	0.00% 0/10 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.	10.0% 1/10 • Number of events 1 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.	0.00% 0/1 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.	— 0/0 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.
General disorders Failure to Thrive	10.0% 1/10 • Number of events 1 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.	10.0% 1/10 • Number of events 1 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.	0.00% 0/1 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.	— 0/0 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.
General disorders Fever	10.0% 1/10 • Number of events 1 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.	0.00% 0/10 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.	0.00% 0/1 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.	— 0/0 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.
Gastrointestinal disorders Gastroenteritis	0.00% 0/10 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.	10.0% 1/10 • Number of events 1 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.	0.00% 0/1 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.	— 0/0 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.
General disorders Hypovolemic shock	0.00% 0/10 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.	0.00% 0/10 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.	100.0% 1/1 • Number of events 1 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.	— 0/0 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.
Blood and lymphatic system disorders Hemolytic Anemia	0.00% 0/10 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.	10.0% 1/10 • Number of events 1 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.	0.00% 0/1 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.	— 0/0 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.
Infections and infestations Herpes simplex Reactivation	0.00% 0/10 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.	10.0% 1/10 • Number of events 2 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.	0.00% 0/1 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.	— 0/0 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.
Metabolism and nutrition disorders Hypernatremia	0.00% 0/10 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.	10.0% 1/10 • Number of events 1 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.	0.00% 0/1 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.	— 0/0 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.
Infections and infestations Lung Infection - COVID-19	10.0% 1/10 • Number of events 1 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.	0.00% 0/10 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.	0.00% 0/1 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.	— 0/0 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.
Infections and infestations Lung Infection -Chlamydia trachomatis	0.00% 0/10 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.	10.0% 1/10 • Number of events 1 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.	0.00% 0/1 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.	— 0/0 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.
Metabolism and nutrition disorders Malnutrition	0.00% 0/10 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.	10.0% 1/10 • Number of events 1 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.	0.00% 0/1 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.	— 0/0 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Pancreatic Adenocarcinoma	10.0% 1/10 • Number of events 1 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.	0.00% 0/10 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.	0.00% 0/1 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.	— 0/0 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.
Respiratory, thoracic and mediastinal disorders Respiratory Failure	10.0% 1/10 • Number of events 2 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.	0.00% 0/10 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.	0.00% 0/1 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.	— 0/0 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.
Infections and infestations Sepsis	20.0% 2/10 • Number of events 2 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.	10.0% 1/10 • Number of events 1 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.	0.00% 0/1 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.	— 0/0 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.
Investigations Septic Shock	20.0% 2/10 • Number of events 3 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.	10.0% 1/10 • Number of events 1 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.	100.0% 1/1 • Number of events 1 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.	— 0/0 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.
Hepatobiliary disorders Sinusoidal Obstruction Syndrome	0.00% 0/10 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.	10.0% 1/10 • Number of events 1 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.	0.00% 0/1 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.	— 0/0 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.
Respiratory, thoracic and mediastinal disorders Throat Pain	10.0% 1/10 • Number of events 1 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.	0.00% 0/10 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.	0.00% 0/1 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.	— 0/0 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.
Infections and infestations Upper Respiratory Infection - Coronavirus	0.00% 0/10 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.	10.0% 1/10 • Number of events 1 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.	0.00% 0/1 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.	— 0/0 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.
Infections and infestations Upper Respiratory Infection - Human Metapneumovirus	0.00% 0/10 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.	10.0% 1/10 • Number of events 1 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.	0.00% 0/1 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.	— 0/0 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.
Infections and infestations Upper Respiratory Infection - Parainfluenza	0.00% 0/10 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.	10.0% 1/10 • Number of events 1 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.	0.00% 0/1 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.	— 0/0 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.
Infections and infestations Urinary Tract Infection	0.00% 0/10 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.	10.0% 1/10 • Number of events 1 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.	0.00% 0/1 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.	— 0/0 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.
Infections and infestations Viremia - Cytomegalovirus	10.0% 1/10 • Number of events 1 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.	10.0% 1/10 • Number of events 1 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.	0.00% 0/1 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.	— 0/0 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.

Other adverse events

Measure	ATG Group I n=10 participants at risk Anti-thymocyte Globulin (ATG) 1.5 mg/kg administered on Day -5, Day -3 and Day -1 of the transplant conditioning regimen. * Fludarabine 30mg/m2 administered on Day -7 through Day -3 of transplant conditioning regimen (if under 60 years old), or on Day -5 through Day -3 of transplant conditioning regimen (if over 60 years old) * Melphalan 140 mg/m2 administered on Day -2 of transplant conditioning regimen. * Total Body Irradiation 2 Gray administered on Day -4, Day -3 of transplant conditioning regimen. * Tocilizumab 8 mg/kg administered on Day -1 of transplant conditioning regimen. Tocilizumab: Tocilizumab 8 mg/kg intravenously administered as a single dose on Day -1 of transplant conditioning regimen Fludarabine: Fludarabine 30 mg/m2 intravenously administered on Day -7, Day -6, Day -5, Day -4, Day -3 of transplant conditioning regimen if under the age of 60. If over the age of 60, Fludarabine 30 mg/m2 intravenously administered on Day -5, Day -4 and Day -3 of transplant conditioning regimen. Melphalan: Melphalan 140 mg/m2 intravenously administered on Day -2 of transplant conditioning regimen. Anti-thymocyte globulin (rabbit): Anti-thymocyte globulin (ATG) 1.5 mg/kg Total Body Irradiation: Total Body Irradiation (TBI) 2 Gray, administered on Day -4 and Day -3 of transplant conditioning regimen	ATG Group II n=10 participants at risk Anti-thymocyte Globulin (ATG) 1.5 mg/kg administered on Day -5, and Day -3 of the transplant conditioning regimen. * Fludarabine 30mg/m2 administered on Day -7 through Day -3 of transplant conditioning regimen (if under 60 years old), or on Day -5 through Day -3 of transplant conditioning regimen (if over 60 years old) * Melphalan 140 mg/m2 administered on Day -2 of transplant conditioning regimen. * Total Body Irradiation 2 Gray administered on Day -4, Day -3 of transplant conditioning regimen. * Tocilizumab 8 mg/kg administered on Day -1 of transplant conditioning regimen. Tocilizumab: Tocilizumab 8 mg/kg intravenously administered as a single dose on Day -1 of transplant conditioning regimen Fludarabine: Fludarabine 30 mg/m2 intravenously administered on Day -7, Day -6, Day -5, Day -4, Day -3 of transplant conditioning regimen if under the age of 60. If over the age of 60, Fludarabine 30 mg/m2 intravenously administered on Day -5, Day -4 and Day -3 of transplant conditioning regimen. Melphalan: Melphalan 140 mg/m2 intravenously administered on Day -2 of transplant conditioning regimen. Anti-thymocyte globulin (rabbit): Anti-thymocyte globulin (ATG) 1.5 mg/kg Total Body Irradiation: Total Body Irradiation (TBI) 2 Gray, administered on Day -4 and Day -3 of transplant conditioning regimen	ATG Group III n=1 participants at risk Anti-thymocyte Globulin (ATG) 1.5 mg/kg administered on Day -5 of the transplant conditioning regimen. * Fludarabine 30mg/m2 administered on Day -7 through Day -3 of transplant conditioning regimen (if under 60 years old), or on Day -5 through Day -3 of transplant conditioning regimen (if over 60 years old) * Melphalan 140 mg/m2 administered on Day -2 of transplant conditioning regimen. * Total Body Irradiation 2 Gray administered on Day -4, Day -3 of transplant conditioning regimen. * Tocilizumab 8 mg/kg administered on Day -1 of transplant conditioning regimen. Tocilizumab: Tocilizumab 8 mg/kg intravenously administered as a single dose on Day -1 of transplant conditioning regimen Fludarabine: Fludarabine 30 mg/m2 intravenously administered on Day -7, Day -6, Day -5, Day -4, Day -3 of transplant conditioning regimen if under the age of 60. If over the age of 60, Fludarabine 30 mg/m2 intravenously administered on Day -5, Day -4 and Day -3 of transplant conditioning regimen. Melphalan: Melphalan 140 mg/m2 intravenously administered on Day -2 of transplant conditioning regimen. Anti-thymocyte globulin (rabbit): Anti-thymocyte globulin (ATG) 1.5 mg/kg Total Body Irradiation: Total Body Irradiation (TBI) 2 Gray, administered on Day -4 and Day -3 of transplant conditioning regimen	ATG Group IV * Fludarabine 30mg/m2 administered on Day -7 through Day -3 of transplant conditioning regimen (if under 60 years old), or on Day -5 through Day -3 of transplant conditioning regimen (if over 60 years old) * Melphalan 140 mg/m2 administered on Day -2 of transplant conditioning regimen. * Total Body Irradiation 2 Gray administered on Day -4, Day -3 of transplant conditioning regimen. * Tocilizumab 8 mg/kg administered on Day -1 of transplant conditioning regimen. Tocilizumab: Tocilizumab 8 mg/kg intravenously administered as a single dose on Day -1 of transplant conditioning regimen Fludarabine: Fludarabine 30 mg/m2 intravenously administered on Day -7, Day -6, Day -5, Day -4, Day -3 of transplant conditioning regimen if under the age of 60. If over the age of 60, Fludarabine 30 mg/m2 intravenously administered on Day -5, Day -4 and Day -3 of transplant conditioning regimen. Melphalan: Melphalan 140 mg/m2 intravenously administered on Day -2 of transplant conditioning regimen. Total Body Irradiation: Total Body Irradiation (TBI) 2 Gray, administered on Day -4 and Day -3 of transplant conditioning regimen
Blood and lymphatic system disorders Anemia	90.0% 9/10 • Number of events 9 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.	100.0% 10/10 • Number of events 10 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.	100.0% 1/1 • Number of events 1 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.	— 0/0 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.
Metabolism and nutrition disorders Anorexia	40.0% 4/10 • Number of events 4 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.	20.0% 2/10 • Number of events 2 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.	0.00% 0/1 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.	— 0/0 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.
Investigations Aspartate aminotransferase increased	30.0% 3/10 • Number of events 3 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.	10.0% 1/10 • Number of events 1 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.	0.00% 0/1 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.	— 0/0 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.
Metabolism and nutrition disorders Hyperglycemia	0.00% 0/10 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.	10.0% 1/10 • Number of events 1 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.	0.00% 0/1 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.	— 0/0 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.
Investigations Acute Graft-versus-Host Disease	30.0% 3/10 • Number of events 3 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.	20.0% 2/10 • Number of events 2 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.	0.00% 0/1 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.	— 0/0 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.
Infections and infestations Viremia - Adenovirus	0.00% 0/10 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.	10.0% 1/10 • Number of events 1 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.	0.00% 0/1 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.	— 0/0 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.
Infections and infestations Adenovirus Colitis	0.00% 0/10 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.	10.0% 1/10 • Number of events 1 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.	0.00% 0/1 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.	— 0/0 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.
Investigations Alanine aminotransferase increased	30.0% 3/10 • Number of events 3 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.	0.00% 0/10 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.	0.00% 0/1 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.	— 0/0 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.
Metabolism and nutrition disorders Hyperkalemia	10.0% 1/10 • Number of events 1 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.	0.00% 0/10 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.	0.00% 0/1 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.	— 0/0 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.
Metabolism and nutrition disorders Hypernatremia	10.0% 1/10 • Number of events 1 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.	10.0% 1/10 • Number of events 1 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.	0.00% 0/1 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.	— 0/0 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.
Metabolism and nutrition disorders Hypoalbuminemia	30.0% 3/10 • Number of events 3 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.	30.0% 3/10 • Number of events 3 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.	100.0% 1/1 • Number of events 1 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.	— 0/0 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.
Metabolism and nutrition disorders Hypocalcemia	30.0% 3/10 • Number of events 3 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.	20.0% 2/10 • Number of events 2 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.	100.0% 1/1 • Number of events 1 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.	— 0/0 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.
Metabolism and nutrition disorders Hypokalemia	40.0% 4/10 • Number of events 4 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.	40.0% 4/10 • Number of events 4 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.	100.0% 1/1 • Number of events 1 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.	— 0/0 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.
Metabolism and nutrition disorders Hypomagnesemia	0.00% 0/10 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.	30.0% 3/10 • Number of events 3 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.	100.0% 1/1 • Number of events 1 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.	— 0/0 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.
Metabolism and nutrition disorders Iron overload	0.00% 0/10 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.	10.0% 1/10 • Number of events 1 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.	0.00% 0/1 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.	— 0/0 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.
Gastrointestinal disorders Mucositis oral	10.0% 1/10 • Number of events 1 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.	10.0% 1/10 • Number of events 1 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.	0.00% 0/1 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.	— 0/0 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.
Investigations Platelet count decreased	60.0% 6/10 • Number of events 6 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.	40.0% 4/10 • Number of events 4 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.	100.0% 1/1 • Number of events 1 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.	— 0/0 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.
Investigations White blood cell decreased	10.0% 1/10 • Number of events 1 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.	30.0% 3/10 • Number of events 3 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.	100.0% 1/1 • Number of events 1 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.	— 0/0 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.
Renal and urinary disorders Urinary retention	0.00% 0/10 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.	10.0% 1/10 • Number of events 1 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.	0.00% 0/1 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.	— 0/0 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.
Infections and infestations Cellulitis	10.0% 1/10 • Number of events 1 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.	10.0% 1/10 • Number of events 1 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.	0.00% 0/1 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.	— 0/0 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.
Vascular disorders Thromboembolic event	10.0% 1/10 • Number of events 1 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.	0.00% 0/10 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.	0.00% 0/1 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.	— 0/0 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.
Infections and infestations Urinary tract infection	10.0% 1/10 • Number of events 1 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.	20.0% 2/10 • Number of events 3 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.	0.00% 0/1 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.	— 0/0 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.
Infections and infestations Clostridium difficile colitis	0.00% 0/10 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.	40.0% 4/10 • Number of events 4 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.	0.00% 0/1 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.	— 0/0 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.
Infections and infestations Upper Respiratory Infection - Parainfluenza	10.0% 1/10 • Number of events 1 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.	30.0% 3/10 • Number of events 3 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.	0.00% 0/1 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.	— 0/0 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.
Infections and infestations Upper Respiratory Infection - Rhinovirus	20.0% 2/10 • Number of events 2 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.	30.0% 3/10 • Number of events 3 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.	0.00% 0/1 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.	— 0/0 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.
Infections and infestations Upper Respiratory Infection - Coronavirus	0.00% 0/10 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.	20.0% 2/10 • Number of events 2 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.	0.00% 0/1 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.	— 0/0 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.
Infections and infestations Upper Respiratory Infection - COVID-19	10.0% 1/10 • Number of events 1 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.	20.0% 2/10 • Number of events 2 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.	0.00% 0/1 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.	— 0/0 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.
Infections and infestations Viremia - Cytomegalovirus	10.0% 1/10 • Number of events 1 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.	30.0% 3/10 • Number of events 3 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.	0.00% 0/1 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.	— 0/0 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.
Infections and infestations Upper Respiratory Infection - Respiratory Syncytial Virus	10.0% 1/10 • Number of events 1 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.	10.0% 1/10 • Number of events 1 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.	0.00% 0/1 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.	— 0/0 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.
Blood and lymphatic system disorders Hemolytic Anemia	10.0% 1/10 • Number of events 1 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.	0.00% 0/10 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.	0.00% 0/1 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.	— 0/0 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.
Infections and infestations Bacteremia	20.0% 2/10 • Number of events 2 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.	30.0% 3/10 • Number of events 3 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.	100.0% 1/1 • Number of events 1 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.	— 0/0 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.
Infections and infestations Infectious Colitis	20.0% 2/10 • Number of events 2 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.	30.0% 3/10 • Number of events 3 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.	0.00% 0/1 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.	— 0/0 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.
Gastrointestinal disorders Diverticulitis	10.0% 1/10 • Number of events 1 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.	0.00% 0/10 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.	0.00% 0/1 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.	— 0/0 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.
Infections and infestations Candida pharyngitis	10.0% 1/10 • Number of events 1 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.	0.00% 0/10 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.	0.00% 0/1 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.	— 0/0 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.
Infections and infestations BK Virus Cystitis	10.0% 1/10 • Number of events 1 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.	0.00% 0/10 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.	0.00% 0/1 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.	— 0/0 • All-cause mortality is being assessed up to 5 years. SAEs and other non-serious AEs were assessed up to 1 year. No subjects were enrolled to ATG Group IV; study enrollment was stopped before accrual reached that cohort.

Additional Information

Alexandra Gomez Arteaga, MD

Weill Cornell Medicine

Phone: 646-962-7950

Email: alg9117@med.cornell.edu

Results disclosure agreements

• Principal investigator is a sponsor employee
• Publication restrictions are in place